Literature DB >> 17904461

Impact of a fluoroquinolone restriction policy in an elderly population.

Muhammad Mamdani1, David McNeely, Gerald Evans, Janet Hux, Paul Oh, Natalie Forde, John Conly.   

Abstract

BACKGROUND: In light of growing concerns of bacterial resistance to fluoroquinolones, the province of Ontario instituted a fluoroquinolone restriction policy in March of 2001. The objective of this study was to examine the immediate impact of this policy on the rates of antibiotic prescription use and infectious disease-related hospitalizations among elderly individuals who are dispensed antibiotics.
METHODS: An interrupted time series analysis was conducted from January 1, 1994, to March 31, 2002, using administrative health care databases covering more than 1.4 million residents of Ontario, Canada, aged 65 years and older. Population rates of antibiotic use and infectious disease-related hospitalizations within 4 weeks after an antibiotic prescription were examined using interventional autoregressive integrated moving average models.
RESULTS: Immediately after the introduction of the fluoroquinolone policy, fluoroquinolone prescription rates decreased to approximately 70% of expected rates (P<.01). Approximately 30% higher than expected use of sulfonamide (P=.01) and urinary anti-infectives (primarily nitrofurantoin and trimethoprim; P<.01) were observed within 1 year after policy implementation. No significant changes in the use of any other groups of antibiotics were observed. Although no significant changes in the rates of overall infection-related hospital admissions among antibiotic users were observed, the rate of hospital admission for gastrointestinal infections was 32% lower than expected in the 1 year after the policy change (P<.01). The hospital admission rate for urinary tract infections was approximately 8% higher than expected (P<.01).
CONCLUSIONS: These findings suggest that formulary restrictions to fluoroquinolones can be implemented effectively to decrease use among an elderly population without adverse impact on hospital admission rates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904461     DOI: 10.1016/j.amjmed.2007.02.028

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

Review 1.  Antibiotic use and population ecology: how you can reduce your "resistance footprint".

Authors:  David M Patrick; James Hutchinson
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

2.  Influences on the start, selection and duration of treatment with antibiotics in long-term care facilities.

Authors:  Nick Daneman; Michael A Campitelli; Vasily Giannakeas; Andrew M Morris; Chaim M Bell; Colleen J Maxwell; Lianne Jeffs; Peter C Austin; Susan E Bronskill
Journal:  CMAJ       Date:  2017-06-26       Impact factor: 8.262

3.  Effect of a Health Care System Respiratory Fluoroquinolone Restriction Program To Alter Utilization and Impact Rates of Clostridium difficile Infection.

Authors:  Katherine M Shea; Athena L V Hobbs; Theresa C Jaso; Jack D Bissett; Christopher M Cruz; Elizabeth T Douglass; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

4.  Fluoroquinolone-induced serious, persistent, multisymptom adverse effects.

Authors:  Beatrice Alexandra Golomb; Hayley Jean Koslik; Alan J Redd
Journal:  BMJ Case Rep       Date:  2015-10-05

Review 5.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

6.  Patients at Risk for Aortic Rupture Often Exposed to Fluoroquinolones during Hospitalization.

Authors:  William C Frankel; Barbara W Trautner; Andrew Spiegelman; Larissa Grigoryan; Scott A LeMaire
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

7.  Antibiotic prescribing patterns and hospital admissions with respiratory and urinary tract infections.

Authors:  Rocío Fernández Urrusuno; Miguel Pedregal González; Ma Amparo Torrecilla Rojas
Journal:  Eur J Clin Pharmacol       Date:  2008-07-08       Impact factor: 2.953

8.  Metronidazole-associated Neurologic Events: A Nested Case-control Study.

Authors:  Nick Daneman; Yi Cheng; Tara Gomes; Jun Guan; Muhammad M Mamdani; Farah E Saxena; David N Juurlink
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

9.  Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice.

Authors:  Scott A LeMaire; Lin Zhang; Wei Luo; Pingping Ren; Alon R Azares; Yidan Wang; Chen Zhang; Joseph S Coselli; Ying H Shen
Journal:  JAMA Surg       Date:  2018-09-19       Impact factor: 14.766

10.  Population-Wide Peer Comparison Audit and Feedback to Reduce Antibiotic Initiation and Duration in Long-Term Care Facilities with Embedded Randomized Controlled Trial.

Authors:  Nick Daneman; Samantha M Lee; Heming Bai; Chaim M Bell; Susan E Bronskill; Michael A Campitelli; Gail Dobell; Longdi Fu; Gary Garber; Noah Ivers; Jonathan M C Lam; Bradley J Langford; Celia Laur; Andrew Morris; Cara Mulhall; Ruxandra Pinto; Farah E Saxena; Kevin L Schwartz; Kevin A Brown
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.